이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고령 환자의 급성 허혈성 뇌졸중 치료를 위한 저용량 테넥테플라제 (DATE-AGING)

2026년 11월 1일 업데이트: Zhenhua Zhou, Southwest Hospital, China

노인 환자의 급성 허혈성 뇌졸중 치료를 위한 저용량 테넥테플라제의 효능과 안전성: 전향적, 다기관, 무작위 대조 연구

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

806

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Anshan, 중국
        • Anshan Changda Hospital
      • Anyang, 중국
        • Anyang People's Hospital
      • Anyang, 중국
        • Huaxian People's Hospital of Henan
      • Baoshan, 중국
        • Baoshan People's Hospital
      • Bijie, 중국
        • People's Hospital of Zhijin County
      • Chongqing, 중국
        • Chongqing University Three Gorges Hospital
      • Chongqing, 중국
        • Chongqing University Jiangjin Hospital
      • Chongqing, 중국
        • Bishan Hospital
      • Chongqing, 중국
        • Chongqing Emergency Medical Center
      • Chongqing, 중국
        • Chongqing University Fuling Hospital
      • Chongqing, 중국
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, 중국
        • People's Hospital Of Xiushan County
      • Chongqing, 중국
        • The People's Hospital of Dazu Chongqing
      • Chongqing, 중국
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, 중국
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, 중국
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, 중국
        • The Seventh People's Hospital of Chongqing
      • Chongqing, 중국
        • Tongliang Hospital
      • Chongqing, 중국
        • Yunyang County People's Hospital
      • Dali, 중국
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, 중국
        • Dazhou Central Hospital
      • Deyang, 중국
        • The People's Hospital of Zhongjiang
      • Guang’an, 중국
        • Guang an People's Hospital
      • Guiyang, 중국
        • Guizhou Provincial People's Hospital
      • Guiyang, 중국
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, 중국
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, 중국
        • Xunxian People's Hospital
      • Heyuan, 중국
        • Heyuan People's Hospital
      • Huanggang, 중국
        • Qichun People's Hosiptal
      • Jianyang, 중국
        • The People's Hospital Of Jianyang City
      • Laixi, 중국
        • Laixi People's Hospital
      • Leshan, 중국
        • People's Hospital of Leshan
      • Leshan, 중국
        • Leshan Geriatric Specialized Hospital
      • Luoyang, 중국
        • Luoyang Mengjin People's Hospital
      • Nanchong, 중국
        • Nanbu People's Hospital
      • Pujiang, 중국
        • Puyang People's Hospital
      • Pujiang, 중국
        • The People's Hospital of Nan Le Xian
      • Shangqiu, 중국
        • People's Hospital of Ningling County
      • Shangqiu, 중국
        • The First People's Hospital of Shangqiu
      • Shaoyang, 중국
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, 중국
        • The People's Hospital of Gaocheng
      • Wuhan, 중국
        • Wuhan Puren Hospital
      • Xiangyang, 중국
        • Xiangyang NO.1 People's Hospital
      • Yibin, 중국
        • The second people's hospital of Yibin
      • Zhumadian, 중국
        • Zhumadian Central Hospital
      • Zhuzhou, 중국
        • Zhuzhou Central Hospital
      • Zigong, 중국
        • Zigong Third People's Hospital
      • Ziyang, 중국
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, 중국, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, 중국, 466300
        • Shenqiu County People's Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

70년 이상 (고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

활성 비교기: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
기간: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
기간: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
기간: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
기간: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
기간: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
기간: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
기간: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
기간: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
기간: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 12월 19일

기본 완료 (실제)

2026년 11월 1일

연구 완료 (실제)

2026년 11월 1일

연구 등록 날짜

최초 제출

2025년 11월 21일

QC 기준을 충족하는 최초 제출

2025년 12월 7일

처음 게시됨 (실제)

2025년 12월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 1일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2025IITDA10

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .